Description: NZOV9 is a semi-adherent cell line derived from a poorly differentiated serous adenocarcinoma of the ovary of a 47 year old female patient.

Description Key Words: Human ovarian adenocarcinoma 

Also Known As: No other names

Organism: Human (Homo sapiens) 

Tissue: Ovary

Growth Properties: Adherent and floating viable cells

Doubling Time: 30 hours

Morphology: Adherent cells have an epithelial morphology the cell line grows in clusters of small cells

Growth Medium: This cell line was established by the depositor in: Alpha modified Minimum Essential Medium (MEM) supplemented with 5% Foetal Bovine Serum (FBS)”, 5 ug/ml Insulin, 5 ug/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5%O₂, 5%CO₂ and 90%N₂.

At CellBank Australia it has been cultured in: Alpha modified Minimum Essential Medium (MEM) supplemented with 10% Foetal Bovine Serum (FBS)”, 5 ug/ml Insulin, 5 ug/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5%CO₂.

Resuscitation: Remove protective cryoflex layer around the ampoule prior to thawing. Thaw the ampoule by gently agitating in a 37°C waterbath; thawing should be rapid (around 2 minutes). A centrifugation step to remove the cryoprotectant after thawing is necessary for this cell line. Recovery from thaw may take 3 days.

Subculturing Procedure:

Medium Renewal: 3 times per week.

Subcultivation Ratio: 1:10 Seeding density 1.0 – 2.0 x10⁴cells/cm². Split subconfluent cultures(70-80%). Harvest the cells using 0.05% Trypsin/EDTA at 37°C for 5 minutes. Combine both adherent and floating cell populations for subculture.

Culture Conditions: Incubate the culture at 37°C with 5%CO₂.

Cryoprotectant Medium: 10% DMSO + 90% FCS

Handling Procedure for Frozen Cells: Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability.

Additional Information: 

• Wild-type for TP53
• Mutant PIK3 enzyme Y1021C
• NZOV9 is aneuploid 2.11x diploid.

Depositor: Professor Bruce Baguley – The University of Auckland, New Zealand

Reference:

Original Reference:

Baguley BC, Marshall ES, Whittaker JR, Dotchin MC, Nixon J, McCrystal MR, Finlay GJ, Matthews JHL, Holdaway KM, van Zijl P.

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

Eur J Cancer 1995; 31A: 230-237.

PubMed 7718330

Cellosaurus: CVCL_LJ73